Titan Pharmaceuticals, Inc.
TTNPNASDAQHealthcare
$2.34
$-0.30(-11.36%)
Market Cap$3112748
P/E Ratio—
52W High$15.15
52W Low$2.33
Titan Pharmaceuticals, Inc. (TTNP) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TTNP · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | ($0.00B) | $0.00B | ($0.00B) | $0.00B | $0.00B |
| Gross Margin %(computed) | — | 100.00% | -226.67% | 86.96% | 90.24% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.01B | $0.01B |
| G&A Expenses | $0.00B | $0.01B | $0.01B | $0.00B | $0.01B |
| Total Operating Expenses | $0.00B | $0.01B | $0.01B | $0.01B | $0.01B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Operating Margin %(computed) | — | — | — | -612.98% | -151.94% |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.02B) |
| Net Margin %(computed) | — | — | — | -531.72% | -428.44% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.23 | $-7.41 | $-15.15 | $-4.06 | $-10.38 |
| Wtd Avg Shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| EBITDA | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) |
| EBITDA Margin %(computed) | — | — | — | -598.49% | -145.91% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Titan Pharmaceuticals, Inc. data
About Titan Pharmaceuticals, Inc. (TTNP) Income Statement
Titan Pharmaceuticals, Inc. (TTNP) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2024, TTNP reported revenue of $0.00B, gross profit of ($0.00B) (gross margin —), and net income of ($0.00B) — a net profit margin of —.
Frequently asked questions
TTNP · 4 questionsTitan Pharmaceuticals, Inc. (TTNP) reported revenue of $0.00B for 2024, down 100.0% year-over-year.
TTNP revenueTTNP salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08